Torrent Pharma acquires Zyg Pharma

Published On 2015-07-19 08:24 GMT | Update On 2015-07-19 08:24 GMT

Torrent Pharmaceuticals Ltd completed acquisition of the city-based Zyg Pharma Ltd for an undisclosed amount, the Ahmedabad-based drug major said on Saturday.

In a regulatory filing to the Bombay Stock Exchange (BSE), Torrent said it had on Friday transacted the entire (100 percent) equity stake of Zyg Pharma in accordance with the share purchase agreement signed on May 5.

"Terms and conditions of the agreement have been satisfied and the entire equity was transferred to the company on July 17," Torrent said in its filing.

The Rs.4,200-crore firm said the acquisition was funded through internal accruals.

Encore group's Zyg Pharma is engaged in manufacturing creams, ointments, gels, lotions and solutions.

Promoted by the Merchant family, the 50-year-old Zyg Pharma has also a manufacturing facility at Pithampur near Indore.

"In line with its strategy to diversify into new therapy segments, the acquisition will help Torrent to strengthen its position in niche dermatological segment in the developed markets like the US and Europe," Zyg said in a statement here.

As a flagship company of the Torrent group, the drug maker has plants at Indrad in Gujarat, Baddi in Himachal Pradesh and Sikkim to produce bulk drugs and formulations for domestic and export markets.Torrent Pharmaceuticals operates in more than 50 countries with over 1000 product registrations globally through its 7 fully owned subsidiares

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Torrent Pharma acquires Zyg Pharma

Similar News

Swasth Nari Sashakt Parivar Abhiyaan concludes, benefits over 6.5 crore women

Jharkhand HC directs Govt to frame HIV guidelines for prison inmates

Bhopal Gas Tragedy: SC issues contempt notices to Health Ministry, ICMR over non-compliance of orders on medical care

Chhattisgarh NHM employees end strike after Government Talks

India conferred with Bloomberg Philanthropies Global Tobacco Control Award

LIC eyes entry into health insurance space by month end

Meerut doctor, 3 Touts arrested for illegal sex determination test

RG Kar Financial Irregularities Case: Court Reprimands CBI for Failing to Provide Documents